Stock Ticker

  • Loading stock data...

Merck & Co’s (NYSE:MRK) Lung Cancer Treatment Dominance With Keytruda Challenged By The Likes Of Regeneron

Over the years, Merck & Co’s (NYSE:MRK) blockbuster cancer treatment, Keytruda, has been the standard first-line treatment alternative for most burdensome lung cancers, but this dominance is about to change. Recently at a cancer research conference, several companies challenged the treatment with their won cancer drugs. Merck’s blockbuster cancer treatment could face competition from new […]

Plandai Biotechnology Inc (OTCMKTS:PLPL) And Generex Biotechnology Corporation (OTCMKTS:GNBT) Issues Promising PRs

Plandai Biotechnology Inc (OTCMKTS:PLPL) and Generex Biotechnology Corporation (OTCMKTS:GNBT) are the two OTC traded stocks that have been the center of attraction after they issued promising PRs. Plandai reported an amendment to its preciously finalized deal with USN Worldwide. Under the new amended deal with USN, it will now expand its Phytofare® sales to USN […]

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Gets FDA Approval For Its EYLEA Injection For Macular Edema Treatment

Boston, MA 10/07/2014 (wallstreetpr) – Pharmaceuticals Inc (NASDAQ:REGN) disclosed that it received the Food and Drug Administration’s approval for its EYELEA injection for Macular Edema treatment after Retinal Vein Occlusion or RVO indication. The company said that patients achieved a 17.0 letter mean improvement with EYLEA injection over the baseline in best-corrected visual acuity or […]

Regeneron Pharmaceuticals Inc (NASDAQ:REGN)’s EYLEA Gets FDA Breakthrough Designation

Boston, MA 09/16/2014 (wallstreetpr) – Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to EYLEA. The drug targets patients with diabetic macular edema (DME) for the treatment of diabetic retinopathy. The Breakthrough Therapy designation was triggered by the positive results obtained from two late-stage trials of the […]

Sanofi SA (ADR) (NYSE:SNY) And Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Reported Success In Phase II Study With Rheumatoid Arthritis Drug

Boston, MA 06/12/2014 (wallstreetpr) – Sanofi SA (ADR) (NYSE:SNY) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced successful results from a Phase III study of experimental drug sarilumab in treating rheumatoid arthritis (RA) in patients who had previously shown no response to  methotrexate (MTX) treatment. The pharmaceutical companies presented their new data which demonstrated that sarilumab is capable […]

Sanofi SA (ADR) (NYSE:SNY) And AstraZeneca Plc (ADR) (NYSE:AZN) Echo Same Tone

Boston, MA 02/06/2014 (wallstreetpr) – Sanofi SA (ADR) (NYSE:SNY), the healthcare provider based in France, reported fourth quarter profits in line with the projections. Although sales were lower on the back of the weaker currency scenario in the emerging markets. Sanofi’s Fourth Quarter Overview Sanofi SA (ADR) (NYSE:SNY)‘s net income for the complete year, excluding charges, […]

Sign Up To Get Our Latest Stocks Alerts